QUT offers a diverse range of student topics for Honours, Masters and PhD study. Search to find a topic that interests you or propose your own research topic to a prospective QUT supervisor. You may also ask a prospective supervisor to help you identify or refine a research topic.
Found 11 matching student topics
Displaying 1–11 of 11 results
Identification of novel melanoma biomarkers using exosomes
Tumour cells excrete exosomes, membrane vesicles (30-150 nm diameter) that encapsulate and transport proteins, metabolites and genetic material. They mediate intercellular communication within the tumor microenvironment, metastasis formation via circulation, and development of drug resistance. Circulating tumor-derived exosomes can be isolated from blood patients as a non-invasive liquid biopsy.The chemical composition and overall properties of the exosomal membranes are expected to be similar to those of parent cell membranes and to modulate blood circulation time, and uptake and targeting of …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Identification and characterisation of IRX4 isoforms as novel targets in prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer-related death in Australian men. There is no cure for advanced prostate cancer patients who develop resistance to currently available treatments. Alternative splicing (AS) is tightly regulated to maintain genomic stability in humans (Liyanage et al 2019). Aberrant RNA splicing of cancer-causing genes has been reported as a major cause of treatment escape in prostate cancer patients. Iroquois-class homeodomain protein 4 (IRX4) is a TALE homeobox transcription factor which has been …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Characterising a DNA repair protein as an anti-cancer therapeutic target and diagnostic marker in brain cancer
Cancer is the single biggest clinical problem facing the world and will account for half of all global deaths by 2030. Even though there have been significant advances in immunotherapy, we are still unable to cure most cancers. New therapeutic targets, individualised to patient needs, must be identified and validated in order to improve cancer outcomes.Brain cancer causes more deaths in people under the age of 40 than any other cancer and more deaths in children than any other disease. …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Genomics and Personalised Health
Targeting a novel adaptive neovascular response of the tumour microenvironment to treat advanced prostate cancer
Prostate cancer (PCa) is a significant healthcare burden in Australia. Androgen signalling inhibition using androgen receptor (AR) antagonists is the principal systemic therapy for advanced PCa. Androgen receptors (AR) are an attractive therapeutic target due to their elevated expression in tumour epithelial cells and the retention of androgen signalling throughout the disease continuum.However, patients eventually develop resistance to treatment, and PCa cells metastasise to distant bone and visceral organs, representing an incurable stage of the disease. Understanding mechanisms that contribute …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Improving platinum-based chemotherapy by targeting drug metabolism in lung cancer
Lung cancer is the deadliest cancer accounting for 18.4% of all cancer-related deaths. Platinum-based chemotherapy remains a key treatment option for most people living with this disease, either as adjuvant therapy or in combination with immunotherapy. However, resistance to therapy is a significant issue in the treatment of lung cancer. Novel therapeutic strategies combined with predictive biomarkers chemotherapy response are needed to transform the clinical management of NSCLC.Our published work has identified novel biomarkers and druggable proteins from deregulated protein …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
- Research centre(s)
- Centre for Genomics and Personalised Health
Targeting leptin's signalling axis to prevent treatment resistance in prostate cancer
Advanced prostate cancer (PCa) is a leading cause of cancer-associated death in Australian men. Anti-androgens, which exploit the tumour’s reliance on androgens for its growth & spread, offer temporary remission in advanced PCa patients, but due to treatment resistance, fail to be curative. A further complication of anti-androgens is that they trigger a deleterious suite of metabolic side-effects resembling obesity/Metabolic syndrome. These symptoms not only impact patient health but promote tumours to be more aggressive & resist treatment. Vital new …
- Study level
- PhD, Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Characterise a novel DNA repair protein as a target for cancer therapies
Data generated in the lab has identified a novel DNA repair protein previously described as a key protein in HSP70/90 complexes. Many pathways of tumourigenesis are mediated by Heat Shock Proteins and HSP70/90 are found significantly upregulated in ovarian cancers. The targeting of HSP70/90 are an emerging therapeutic avenue for the treatment of ovarian cancer. Supporting this, an inhibitor of HSP90 has been shown to sensitise breast cancer cells to PARP inhibitors and paclitaxel.Our preliminary data indicates that this new …
- Study level
- Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Therapeutic opportunities targeting epigenetic-metabolism crosswalks in cancer
Epigenetic and metabolic pathways in cancer cells are highly interconnected. Epigenetic landscape in cancer cells is modified by oncogene-driven metabolic changes. Metabolites modulate the activities of epigenetic modifying enzymes to regulate the expression of specific genes. Conversely, epigenetic deregulation that occurs in cancer affect the expression of metabolic genes, thereby altering the metabolome. These changes all coordinately enhance cancer cell proliferation, metastasis and therapy resistance.The overall aim of the project is to understand the link between the activity of epigenetic …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Testing a promising targeted therapeutic for triple-negative breast cancer
Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and cannot be treated with the available hormonal or targeted drugs used for other breast cancer subtypes. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and metastases early during disease progression. There is an urgent clinical need to develop improved treatment strategies for these women since the median survival of patients with metastatic TNBC …
- Study level
- PhD, Master of Philosophy
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Using a natural β-carboline dimer compound to target metabolic vulnerabilities linked to glycolysis in prostate cancer
Prostate cancer is an androgen dependent cancer and treatments are aimed at preventing activation of the androgen receptor. Part of the development of resistance to therapies involves prostate cancers reprogramming their metabolism to overcome metabolic stress induced by these therapies and support growth and survival. This reprogramming involves increases in the rate of glycolysis and intermediate pathways branching from glycolysis. Previously in our laboratory, the natural compound, beta-carboline dimer, BD, was identified to have potent effects on cell viability, cell …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
A novel molecular targeted therapy for anaplastic prostate cancer
In advanced PCa, where the cancer has spread into the bone and other organs, the emergence of treatment resistance remains inevitable. For decades the primary form of treatment in advanced PCa has been to target the production and actions of male sex hormones, androgens, the primary developmental and survival factor of prostate tissue. While these therapies result in tumour regression and cancer control, this is temporary and treatment resistance occurs, referred to as castrate resistant prostate cancer (CRPC). In the …
- Study level
- Master of Philosophy, Honours
- Faculty
- Faculty of Health
- School
- School of Biomedical Sciences
Contact us
If you have questions about the best options for you, the application process, your research topic, finding a supervisor or anything else, get in touch with us today.